Literature DB >> 26408403

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.

Maria Vassilakopoulou1, Margaritis Avgeris2, Vamsidhar Velcheti1, Vassiliki Kotoula3, Theodore Rampias4, Kyriakos Chatzopoulos5, Christos Perisanidis6, Christos K Kontos2, Aris I Giotakis7, Andreas Scorilas2, David Rimm1, Clarence Sasaki4, George Fountzilas5, Amanda Psyrri8.   

Abstract

PURPOSE: Programmed death-ligand 1 (PD-L1; also known as CD274 or B7-H1) expression represents a mechanism of immune escape for cancer. Our purpose was to characterize tumor PD-L1 expression and associated T-cell infiltration in primary laryngeal squamous cell carcinomas (SCC). EXPERIMENTAL
DESIGN: A well-annotated cohort of 260 operable primary laryngeal SCCs [formalin-fixed paraffin-embedded (FFPE) specimens] was morphologically characterized for stromal tumor-infiltrating lymphocytes (TIL), on hematoxylin/eosin-stained whole sections and for PD-L1 mRNA expression by qRT-PCR in FFPE specimens. For PD-L1 protein expression, automated quantitative protein analysis (AQUA) was applied on tissue microarrays consisting of two cores from these tumors. In addition, PD-L1 mRNA expression in fresh-frozen tumors and normal adjacent tissue specimens was assessed in a second independent cohort of 89 patients with primary laryngeal SCC.
RESULTS: PD-L1 mRNA levels were upregulated in tumors compared with surrounding normal tissue (P = 0.009). TILs density correlated with tumor PD-L1 AQUA levels (P = 0.021). Both high TILs density and high PD-L1 AQUA levels were significantly associated with superior disease-free survival (DFS; TILs: P = 0.009 and PD-L1: P = 0.044) and overall survival (OS; TILs: P = 0.015 and PD-L1: P = 0.059) of the patients and retained significance in multivariate analysis.
CONCLUSIONS: Increased TILs density and PD-L1 levels are associated with better outcome in laryngeal squamous cell cancer. Assessment of TILs and PD-L1 expression could be useful to predict response to immune checkpoint inhibitors. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26408403     DOI: 10.1158/1078-0432.CCR-15-1543

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  79 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Alternative Splicing Detection Tool-a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis.

Authors:  Panagiotis G Adamopoulos; Margarita C Theodoropoulou; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

3.  Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.

Authors:  Mathias Fiedler; Florian Weber; Matthias G Hautmann; Frank Haubner; Torsten E Reichert; Christoph Klingelhöffer; Stephan Schreml; Johannes K Meier; Arndt Hartmann; Tobias Ettl
Journal:  Clin Oral Investig       Date:  2017-03-18       Impact factor: 3.573

Review 4.  Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.

Authors:  Marios A Diamantopoulos; Panagiotis Tsiakanikas; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

5.  Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.

Authors:  Chuangzhong Deng; Zaishang Li; Shengjie Guo; Peng Chen; Xiaofeng Chen; Qianghua Zhou; Jieping Chen; Xingsu Yu; Xiaoliang Wu; Wenjuan Ma; Qiankun Xie; Yunlin Ye; Yonghong Li; Zike Qin; Zhuowei Liu; Ranyi Liu; Zhenfeng Zhang; Kai Yao; Hui Han; Fangjian Zhou
Journal:  Oncoimmunology       Date:  2016-12-22       Impact factor: 8.110

Review 6.  Towards tumor immunodiagnostics.

Authors:  Helen Kourea; Vassiliki Kotoula
Journal:  Ann Transl Med       Date:  2016-07

7.  PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs.

Authors:  Austin K Mattox; Jina Lee; William H Westra; Robert H Pierce; Ronald Ghossein; William C Faquin; Thomas J Diefenbach; Luc G Morris; Derrick T Lin; Lori J Wirth; Armida Lefranc-Torres; Eiichi Ishida; Patrick D Chakravarty; Lauren Johnson; Yang C Zeng; Huabiao Chen; Mark C Poznansky; Neil M Iyengar; Sara I Pai
Journal:  Cancer Res       Date:  2017-09-25       Impact factor: 12.701

8.  PD-L1 as a biomarker in NSCLC: challenges and future directions.

Authors:  Matthen Mathew; Rachael A Safyan; Catherine A Shu
Journal:  Ann Transl Med       Date:  2017-09

9.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.

Authors:  Thomas A Mace; Reena Shakya; Jason R Pitarresi; Benjamin Swanson; Christopher W McQuinn; Shannon Loftus; Emily Nordquist; Zobeida Cruz-Monserrate; Lianbo Yu; Gregory Young; Xiaoling Zhong; Teresa A Zimmers; Michael C Ostrowski; Thomas Ludwig; Mark Bloomston; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Gut       Date:  2016-10-21       Impact factor: 23.059

10.  Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.

Authors:  Qian-Kun Xie; Yu-Jie Zhao; Tao Pan; Ning Lyu; Lu-Wen Mu; Shao-Long Li; Mu-De Shi; Zhen-Feng Zhang; Peng-Hui Zhou; Ming Zhao
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.